Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

WR 238605

Known as: WR-238605 
 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

tafenoquine

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2004
2004
Simultaneous Modeling of the Pharmacokinetics and Methemoglobin Pharmacodynamics of an 8-Aminoquinoline Candidate Antimalarial (WR 238605)
Methemoglobin (MHb) formation can be a clinically significant and dose-limiting side effect of 8-aminoquinoline antimalarials… Expand
2003
2003
Transmission-blocking activity of tafenoquine (WR-238605) and artelinic acid against naturally circulating strains of Plasmodium vivax in Thailand.
The sporontocidal activity of tafenoquine (WR-238605) and artelinic acid was determined against naturally circulating isolates of… Expand
  • table 1
  • table 2
  • table 3
  • table 4
2003
2003
Blood schizontocidal activity of WR 238605 (Tafenoquine) against Plasmodium cynomolgi and Plasmodium fragile infections in rhesus monkeys.
A new 8-aminoquinoline antimalarial WR 238605 (Tafenoquine), developed initially as a primaquine alternative for prevention of… Expand
Highly Cited
2001
Highly Cited
2001
A new primaquine analogue, tafenoquine (WR 238605), for prophylaxis against Plasmodium falciparum malaria.
We tested tafenoquine (WR 238605), a new long-acting 8-aminoquinoline, for its ability to prevent malaria in an area that is… Expand
Highly Cited
1999
Highly Cited
1999
Randomized dose-ranging study of the safety and efficacy of WR 238605 (Tafenoquine) in the prevention of relapse of Plasmodium vivax malaria in Thailand.
WR 238605 is an 8-aminoquinoline developed for the radical cure of Plasmodium vivax. Forty-four P. vivax-infected patients were… Expand
Highly Cited
1998
Highly Cited
1998
First-time-in-humans safety and pharmacokinetics of WR 238605, a new antimalarial.
WR 238605 is an 8-aminoquinoline drug currently under development for prophylaxis and treatment of malaria. Preclinical studies… Expand
  • figure 1
  • table 1
  • table 2
  • figure 2
  • table 3
Highly Cited
1998
Highly Cited
1998
Prophylaxis of Plasmodium falciparumInfection in a Human Challenge Model with WR 238605, a New 8-Aminoquinoline Antimalarial
ABSTRACT The prophylactic efficacy of WR 238605, a primaquine analog, was studied with a human Plasmodium falciparum challenge… Expand
  • figure 1
  • table 1
Highly Cited
1997
Highly Cited
1997
WR 238605, chloroquine, and their combinations as blood schizonticides against a chloroquine-resistant strain of Plasmodium vivax in Aotus monkeys.
The compound WR 238605 is a primaquine analog being developed by the U.S. Army as an antimalarial drug. Currently, there is no… Expand
1995
1995
Metabolism of a candidate 8-aminoquinoline antimalarial agent, WR 238605, by rat liver microsomes.
The in vitro metabolism of the 8-aminoquinoline, 8-(4-amino-1- methylbutylamino-2,6-dimethoxy-4-methyl-5-(3-trifluromethyl… Expand
1990
1990
Sporontocidal activity of the antimalarial WR-238605 against Plasmodium berghei ANKA in Anopheles stephensi.
  • R. Coleman
  • The American journal of tropical medicine and…
  • 1990
    • Corpus ID: 36400613
The influence of WR-238605 (8-[(4-amino-1-methyl-butyl) amino]-2,6-dimethoxy-4-methyl-5-[3-tri-fluoromethylphenoxyl] quinoline… Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE